Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 2 Interventional Results available

Melanoma Vaccine With Peptides and Leuprolide

NCT00254397
Conditions
Melanoma
Interventions
Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprolide Acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
Drug · Diagnostic Test · Procedure
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Conditions
Puberty, Precocious
Interventions
Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 16 more
Conditions
Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions
First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT, Cyclophosphamide, Methotrexate, Tacrolimus, Total Body Irradiation, Busulfan, Fludarabine, Second Allogeneic Bone Marrow Transplantation
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Oklahoma City, Oklahoma
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Conditions
Low-Grade Serous Ovarian Cancer
Interventions
Avutometinib, Defactinib, Letrozole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Atlanta, Georgia • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

NCT04760691
Conditions
HIV, Prophylaxis, Transgender
Interventions
Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
Interventions
Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
Conditions
Early Breast Cancer
Interventions
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
85
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 2 Interventional Results available

Bay98-7196, Dose Finding / POC Study

NCT02203331
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Conditions
Breast Neoplasms
Interventions
Exemestane, Letrozole, Anastrozole, Leuprolide Acetate, Pertuzumab, Trastuzumab
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Newnan, Georgia • Zion, Illinois